HRP20201896T1 - Bakterijske komponente cijepiva staphylococcus aureus i njihove uporabe - Google Patents
Bakterijske komponente cijepiva staphylococcus aureus i njihove uporabe Download PDFInfo
- Publication number
- HRP20201896T1 HRP20201896T1 HRP20201896TT HRP20201896T HRP20201896T1 HR P20201896 T1 HRP20201896 T1 HR P20201896T1 HR P20201896T T HRP20201896T T HR P20201896TT HR P20201896 T HRP20201896 T HR P20201896T HR P20201896 T1 HRP20201896 T1 HR P20201896T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- polypeptide
- gene
- staphylococcus aureus
- imi
- Prior art date
Links
- 241000191967 Staphylococcus aureus Species 0.000 title claims 2
- 229960001212 bacterial vaccine Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 241000344863 Staphylococcus aureus subsp. aureus COL Species 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 208000031462 Bovine Mastitis Diseases 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
Claims (8)
1. Farmaceutski pripravak za uporabu u prevenciji i / ili liječenju stafilokokne intramamarne infekcije (IMI) kod sisavca, naznačen time što navedeni pripravak sadrži:
(1) najmanje jedno sredstvo, pri čemu je navedeno sredstvo:
(i) polipeptid kodiran genom SACOL0029, zasnovan na genskoj nomenklaturi iz genoma Staphylococcus aureus COL (SACOL) prikazanom u NCBI referentnoj sekvenci NC_002951.2, pri čemu navedeni polipeptid sadrži aminokiselinsku sekvencu proteina br. YP_184940.1 dostupno putem GenBank-a;
(ii) polipeptid koji ima najmanje 95% identiteta sa (i); ili
(iii) nukleinsku kiselinu koja kodira polipeptid bilo kojeg od (i) do (ii); ili
(2) sredstvo, pri čemu je navedeno sredstvo živi oslabljeni oblik Staphyloccocus aureus koji sadrži mutaciju gena SACOL0029, pri čemu je mutacija brisanje, umetanje ili supstitucija jednog ili više nukleotida.
2. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je sisavac krava.
3. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni stafilokokni IMI, poželjno povezan s goveđim mastitisom, uzrokuje jedan ili više sojeva Staphylococcus aureus.
4. Farmaceutski pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, sadrži kombinaciju sredstava.
5. Farmaceutski pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što nadalje sadrži katalizator, pri čemu je navedeni katalizator poželjno stipsa, emulgirano ulje, ciklički-diguanozin-5'-monofosfat (c-di-GMP), polifosfazin ili patogen-povezani molekularni uzorci (PAMPS), i pri čemu su PAMPS poželjnije nemetilirani dinukleotidi (CpG) ili mikrobni polisaharidi.
6. Farmaceutski pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što navedeni farmaceutski pripravak nadalje sadrži jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
7. Komplet za uporabu u dijagnosticiranju stafilokokne intramamarne infekcije (IMI), naznačen time što sadrži:
(a) najmanje jedan ligand koji se specifično veže na polipeptid kodiran genom SACOL0029, na temelju genske nomenklaturu iz genoma Staphylococcus aureus COL (SACOL) prikazanom u NCBI referentnoj sekvenci NC_002951.2, pri čemu navedeni polipeptid sadrži aminokiselinsku sekvencu proteina br. YP_184940.1 dostupno putem GenBank-a;
(b) upute za uporabu pribora za dijagnozu stafilokoknog IMI.
8. Komplet za uporabu u skladu s patentnim zahtjevom 7, koji sadrži kombinaciju liganada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31467010P | 2010-03-17 | 2010-03-17 | |
| PCT/CA2011/050145 WO2011113160A1 (en) | 2010-03-17 | 2011-03-17 | Bacterial vaccine components from staphylococcus aureus and uses thereof |
| EP11755607.6A EP2547361B1 (en) | 2010-03-17 | 2011-03-17 | Bacterial vaccine components from staphylococcus aureus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201896T1 true HRP20201896T1 (hr) | 2021-04-16 |
Family
ID=44648395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201896TT HRP20201896T1 (hr) | 2010-03-17 | 2020-11-27 | Bakterijske komponente cijepiva staphylococcus aureus i njihove uporabe |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US8889150B2 (hr) |
| EP (1) | EP2547361B1 (hr) |
| CA (2) | CA3133182A1 (hr) |
| DK (1) | DK2547361T3 (hr) |
| ES (1) | ES2834652T3 (hr) |
| HR (1) | HRP20201896T1 (hr) |
| HU (1) | HUE052610T2 (hr) |
| LT (1) | LT2547361T (hr) |
| PT (1) | PT2547361T (hr) |
| SI (1) | SI2547361T1 (hr) |
| WO (1) | WO2011113160A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2547361T (pt) * | 2010-03-17 | 2020-12-07 | Socpra Sciences Et Genie Sec | Componentes de vacina bacteriana de staphylococcus aureus e suas utilizações |
| EP2863223B1 (en) | 2012-06-13 | 2018-07-25 | Asahi Kasei Kabushiki Kaisha | Method for detecting specific substances in milk |
| WO2018013865A1 (en) * | 2016-07-13 | 2018-01-18 | uBiome, Inc. | Method and system for microbial pharmacogenomics |
| JP6387063B2 (ja) * | 2016-09-30 | 2018-09-05 | 旭化成株式会社 | 乳汁中の特定物質を検出する方法 |
| NZ751880A (en) | 2016-10-21 | 2023-04-28 | Socpra Sciences Et Genie Sec | Vaccine constructs and uses thereof against staphylococcus infections |
| US20210353748A1 (en) * | 2018-09-27 | 2021-11-18 | University Of Florida Research Foundation, Incorporated | TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US20220185852A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288774C (en) | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US6380370B1 (en) * | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| PL229487B1 (pl) | 2002-11-12 | 2018-07-31 | Brigham & Womens Hospital Inc | Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego |
| CN1569893A (zh) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
| KR100729954B1 (ko) | 2004-12-01 | 2007-06-20 | 주식회사 엘지생명과학 | Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법 |
| WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| EP2490598A1 (en) | 2009-10-21 | 2012-08-29 | Thompson Surgical Instruments, Inc. | Retractor system for anterior cervical spine surgery |
| PT2547361T (pt) * | 2010-03-17 | 2020-12-07 | Socpra Sciences Et Genie Sec | Componentes de vacina bacteriana de staphylococcus aureus e suas utilizações |
-
2011
- 2011-03-17 PT PT117556076T patent/PT2547361T/pt unknown
- 2011-03-17 CA CA3133182A patent/CA3133182A1/en active Pending
- 2011-03-17 DK DK11755607.6T patent/DK2547361T3/da active
- 2011-03-17 US US13/583,054 patent/US8889150B2/en active Active
- 2011-03-17 HU HUE11755607A patent/HUE052610T2/hu unknown
- 2011-03-17 EP EP11755607.6A patent/EP2547361B1/en active Active
- 2011-03-17 LT LTEP11755607.6T patent/LT2547361T/lt unknown
- 2011-03-17 CA CA2792956A patent/CA2792956C/en active Active
- 2011-03-17 ES ES11755607T patent/ES2834652T3/es active Active
- 2011-03-17 WO PCT/CA2011/050145 patent/WO2011113160A1/en active Application Filing
- 2011-03-17 SI SI201131934T patent/SI2547361T1/sl unknown
-
2014
- 2014-10-14 US US14/513,987 patent/US9566322B2/en active Active
-
2016
- 2016-11-07 US US15/344,688 patent/US10029004B2/en active Active
-
2018
- 2018-06-20 US US16/013,494 patent/US10576139B2/en active Active
-
2020
- 2020-01-22 US US16/749,556 patent/US11065322B2/en active Active
- 2020-01-22 US US16/749,597 patent/US11129884B2/en active Active
- 2020-11-27 HR HRP20201896TT patent/HRP20201896T1/hr unknown
-
2021
- 2021-06-25 US US17/358,086 patent/US20210322532A1/en not_active Abandoned
- 2021-08-24 US US17/410,908 patent/US20210393762A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10576139B2 (en) | 2020-03-03 |
| US20200188501A1 (en) | 2020-06-18 |
| US20130064845A1 (en) | 2013-03-14 |
| US20170095548A1 (en) | 2017-04-06 |
| SI2547361T1 (sl) | 2021-01-29 |
| US10029004B2 (en) | 2018-07-24 |
| ES2834652T3 (es) | 2021-06-18 |
| US8889150B2 (en) | 2014-11-18 |
| US20210322532A1 (en) | 2021-10-21 |
| LT2547361T (lt) | 2020-12-28 |
| WO2011113160A1 (en) | 2011-09-22 |
| EP2547361A4 (en) | 2014-03-19 |
| CA2792956C (en) | 2021-11-16 |
| EP2547361B1 (en) | 2020-10-28 |
| US9566322B2 (en) | 2017-02-14 |
| US20200147197A1 (en) | 2020-05-14 |
| EP2547361A1 (en) | 2013-01-23 |
| DK2547361T3 (da) | 2020-11-23 |
| PT2547361T (pt) | 2020-12-07 |
| US20180289791A1 (en) | 2018-10-11 |
| HUE052610T2 (hu) | 2021-05-28 |
| US20150132335A1 (en) | 2015-05-14 |
| US20210393762A1 (en) | 2021-12-23 |
| CA2792956A1 (en) | 2011-09-22 |
| US11129884B2 (en) | 2021-09-28 |
| CA3133182A1 (en) | 2011-09-22 |
| US11065322B2 (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201896T1 (hr) | Bakterijske komponente cijepiva staphylococcus aureus i njihove uporabe | |
| HRP20200727T1 (hr) | Pripravci i metode povezane s varijantama proteina a (spa) | |
| RU2018107249A (ru) | Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики | |
| JP2010166916A5 (hr) | ||
| Golding et al. | Whole-genome sequence of livestock-associated ST398 methicillin-resistant Staphylococcus aureus isolated from humans in Canada | |
| JP2008538183A5 (hr) | ||
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| BRPI1008663B8 (pt) | bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago | |
| CR7926A (es) | Inhibidores peptidicos de toxinas derivadas de la ll-37 | |
| JP2011503102A5 (hr) | ||
| HRP20161320T4 (hr) | Kimerni polipeptidi i njihova upotreba u dekoloniziranju bakterija | |
| WO2015089073A3 (en) | Compositions and methods for phagocyte delivery of anti-staphylococcal agents | |
| EA201001212A8 (ru) | Лечение микробных инфекций | |
| Rajan et al. | Genotyping of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) in a tertiary care centre in Mysore, South India: ST2371-SCCmec IV emerges as the major clone | |
| Morrisette et al. | Bacteriophage-antibiotic combinations for Enterococcus faecium with varying bacteriophage and daptomycin susceptibilities | |
| BR112013001577A2 (pt) | conjugados de carboidrato e dihidorxiclorina e clorina <225>-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real | |
| JP2017526627A5 (hr) | ||
| JP2018121640A5 (hr) | ||
| Molina et al. | The emerging role of β-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections | |
| Chen et al. | Control of methicillin-resistant Staphylococcus aureus pneumonia utilizing TLR2 agonist Pam3CSK4 | |
| WO2008108830A3 (en) | Immunogenic and therapeutic compositions for streptococcus pyogenes | |
| JP6204930B2 (ja) | 多価ワクチンによる黄色ブドウ球菌感染症からの保護 | |
| MX2011009548A (es) | Composiciones y metodos para la eliminacion de bacterias gram-negativas. | |
| HRP20201683T1 (hr) | Imunogeni pripravak namijenjen upotrebi u terapiji | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections |